Searching for "nhs" found 7

UK National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse place today than in the early days of the COVID-19 pandemic and that pressures on hospitals, maternity care and services…

United Kingdom After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack of consistency and coordination as well as cases of discrimination within the system. As a result of the report, the…

Thailand Dr Jadej Thammatacharee, deputy secretary general of the Thai National Health Security Office (NHSO), outlines the evolution of Thailand’s universal healthcare coverage program, the challenges inherent in its implementation, and the Thai government’s commitment to working with industry to overcome them.   We believe that every Thai should feel secure,…

UK Today NHS England have released their long-term plan to ensure the future of the NHS and the continued care of UK patients.   The plan is backed by 20.5 billion – the biggest funding settlement in NHS history. Informed by NHS staff and patients, the plan sets out their priorities…

BIOTECH This week the NHS becomes the first in the world to routinely offer access to breakthrough genomic medicine. Today (1st October 2018) marks a huge stride in ‘precision medicine’ in the UK as the NHS begins to offer gene therapies tailored to individual patients. Hospitals across England have connected to specialist…

Cancer Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after receiving European Commission (EC) approval. “It’s fantastic news for children and young people with this form of leukaemia.” Prof Charles Swanton, Cancer Research UK’s Dubbed as the future of cancer therapy, Kymriah, Novartis’ gene-modifying treatment…

Merck Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal with NHS England for its innovative new multiple sclerosis (MS) treatment, Mavenclad and how this deal stands as a new…